

Table SI. Univariate and multivariate logistic results

	Univariate logistic analyses results				Multivariate logistic analyses results ^d			
	OR	95% CI	p-value	Adjusted p-value ^e	OR	95% CI	p-value	Adjusted p-value ^e
Age at baseline (years)	1.00	0.99–1.02	0.537	0.614	1.08	1.00–1.17	0.049	0.166
Age at baseline(square)	1.00	1.00–1.00	0.869	0.869	1.00	1.00–1.00	0.061	0.166
Men	1.13	0.76–1.68	0.551	0.614	1.20	0.77–1.86	0.416	0.541
History of any eye disease ^{a,b}	2.97	1.76–5.01	0.000	0.000	–	–	–	–
History of allergic eye disease ^a	2.91	1.41–6.02	0.004	0.013	–	–	–	–
History of non-allergic eye disease ^b	3.00	1.69–5.35	0.000	0.000	–	–	–	–
Use of ophthalmic drugs at baseline ^c	5.16	3.11–8.58	0.000	0.000	–	–	–	–
No history of any eye disease and no ophthalmic drugs at baseline, reference	–	–	0.000	0.000	–	–	0.000	0.000
History of any eye disease and no ophthalmic drugs at baseline	1.66	0.82–3.37	0.163	0.256	2.04	0.96–4.32	0.064	0.166
History of any eye disease and ophthalmic drugs at baseline	5.72	2.64–12.40	0.000	0.000	5.16	2.30–11.56	0.000	0.000
History of self-reported episodic acute allergic conjunctivitis	1.65	1.10–2.49	0.016	0.039	1.33	0.77–2.29	0.303	0.438
Allergic asthma	1.23	0.83–1.83	0.307	0.422	0.97	0.61–1.53	0.879	0.879
Allergic rhinitis	1.37	0.90–2.10	0.141	0.254	0.93	0.53–1.63	0.798	0.865
Food allergy	1.62	1.09–2.39	0.016	0.039	1.48	0.94–2.34	0.088	0.184
History of rosacea	0.52	0.06–4.68	0.558	0.614	–	–	–	–
EASI score at baseline	1.02	1.00–1.03	0.036	0.079	–	–	–	–
EASI score at baseline, per severity category			0.085	0.170	–	–	–	–
Mild AD (EASI 0.1–5.9), reference	–	–	–	–	–	–	0.099	0.184
Moderate AD (EASI 6.0–22.9)	1.23	0.53–2.87	0.628	0.658	1.38	0.54–3.57	0.502	0.593
Severe AD (EASI 23.0–72.0)	1.89	0.79–4.48	0.150	0.254	2.12	0.80–5.61	0.131	0.213
IGA score at baseline	1.07	0.86–1.33	0.542	0.614	–	–	–	–
AD eyelid involvement in the past year	3.73	1.70–8.19	0.001	0.004	–	–	–	–
Eosinophilia ($\geq 0.45 \times 10^9/l$) at baseline	1.30	0.86–1.95	0.210	0.308	–	–	–	–

^aAtopic keratoconjunctivitis; vernal keratoconjunctivitis; giant papillary conjunctivitis. ^bKeratoconus; pellucid marginal degeneration; keratitis; uveitis; herpetic keratitis; blepharitis; glaucoma; cataract; macula oedema; amblyopia; meibomitis; retinal ablation. ^cKetotifen; cromoglicic acid; levocabastine; dextran/hypromellose; sodium hyaluronate/carbomer; other lubricant eyedrops; oxytetracycline/hydrocortisone; dexamethasone; fluormetholone liquifilm; cyclosporine; tobramycin/dexamethasone; prednisolone; hydrocortisone; tacrolimus eye ointment; pimecrolimus skin ointment; chloramphenicol; prostaglandin f-analogue; beta-blocker eyedrops; other ophthalmic drugs. ^dIn the multivariate analysis, some variables were combined, categorized or excluded. History of any eye disease was combined with the use of ophthalmic medication at baseline. Atopic dermatitis (AD) severity categories based on Eczema Area and Severity Index (EASI) scores were included in the multivariate analyses. AD eyelid involvement in the past year was excluded from the multivariate analyses due to a high number of missing values. ^ep-values were adjusted for multiple testing using the Benjamini-Hochberg procedure (21), which controls false discovery rate (FDR). FDR adjusted p-values < 0.05 were considered statistically significant. IGA scale: Investigator's Global Assessment Scale; IQR: interquartile range; OR: odds ratio; SD: standard deviation. Bold values indicate statistical significance.